Cargando…
Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
Aim: To explore the immunoregulatory effects of circ_CELF1 in non-small cell lung cancer (NSCLC). Methods: The mRNA level of circ_CELF1 in primary tissue samples was analyzed by qRT-PCR. The assays of CCK-8, colony formation, wound healing as well as Transwell were employed for measurement of cancer...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660608/ https://www.ncbi.nlm.nih.gov/pubmed/34788230 http://dx.doi.org/10.18632/aging.203576 |
_version_ | 1784613223955169280 |
---|---|
author | Ge, Wen Chi, Hao Tang, Hua Xu, Jianjun Wang, Jing Cai, Wan Ma, Haitao |
author_facet | Ge, Wen Chi, Hao Tang, Hua Xu, Jianjun Wang, Jing Cai, Wan Ma, Haitao |
author_sort | Ge, Wen |
collection | PubMed |
description | Aim: To explore the immunoregulatory effects of circ_CELF1 in non-small cell lung cancer (NSCLC). Methods: The mRNA level of circ_CELF1 in primary tissue samples was analyzed by qRT-PCR. The assays of CCK-8, colony formation, wound healing as well as Transwell were employed for measurement of cancer cell malignant transformation. The murine subcutaneous tumor model was used to assess the tumorigenesis of NSCLC in vivo. The assays of circRNA precipitation, RNA immunoprecipitation, and luciferase reporter were performed to study the relationship between circ_CELF1, miR-491-5p, and EGFR. Results: circ_CELF1 is upregulated in primary cancer tissues from patients with NSCLC, and a high level of circ_CELF1, is associated with malignant characteristics and poor outcomes of patients with NSCLC. Enforced expression of circ_CELF1 exacerbated the malignant transformation of NSCLC cells. Mechanistically, through directly interacting with miR-491-5p, circ_CELF1 acted as a miRNA sponge that increased the expression of the miR-491-5p target gene EGFR, eventually promoting the progression of NSCLC and increasing cancer resistance to immunotherapy. Conclusion: Our data demonstrate that upregulation of circ_CELF1 elicits both oncogenic and immunoregulatory effects on the development of NSCLC. We believe that circ_CELF1 can act as a potential therapeutic target for the treatment of NSCLC. |
format | Online Article Text |
id | pubmed-8660608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-86606082021-12-13 Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis Ge, Wen Chi, Hao Tang, Hua Xu, Jianjun Wang, Jing Cai, Wan Ma, Haitao Aging (Albany NY) Research Paper Aim: To explore the immunoregulatory effects of circ_CELF1 in non-small cell lung cancer (NSCLC). Methods: The mRNA level of circ_CELF1 in primary tissue samples was analyzed by qRT-PCR. The assays of CCK-8, colony formation, wound healing as well as Transwell were employed for measurement of cancer cell malignant transformation. The murine subcutaneous tumor model was used to assess the tumorigenesis of NSCLC in vivo. The assays of circRNA precipitation, RNA immunoprecipitation, and luciferase reporter were performed to study the relationship between circ_CELF1, miR-491-5p, and EGFR. Results: circ_CELF1 is upregulated in primary cancer tissues from patients with NSCLC, and a high level of circ_CELF1, is associated with malignant characteristics and poor outcomes of patients with NSCLC. Enforced expression of circ_CELF1 exacerbated the malignant transformation of NSCLC cells. Mechanistically, through directly interacting with miR-491-5p, circ_CELF1 acted as a miRNA sponge that increased the expression of the miR-491-5p target gene EGFR, eventually promoting the progression of NSCLC and increasing cancer resistance to immunotherapy. Conclusion: Our data demonstrate that upregulation of circ_CELF1 elicits both oncogenic and immunoregulatory effects on the development of NSCLC. We believe that circ_CELF1 can act as a potential therapeutic target for the treatment of NSCLC. Impact Journals 2021-11-17 /pmc/articles/PMC8660608/ /pubmed/34788230 http://dx.doi.org/10.18632/aging.203576 Text en Copyright: © 2021 Ge et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Ge, Wen Chi, Hao Tang, Hua Xu, Jianjun Wang, Jing Cai, Wan Ma, Haitao Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis |
title | Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis |
title_full | Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis |
title_fullStr | Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis |
title_full_unstemmed | Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis |
title_short | Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis |
title_sort | circular rna celf1 drives immunosuppression and anti-pd1 therapy resistance in non-small cell lung cancer via the mir-491-5p/egfr axis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660608/ https://www.ncbi.nlm.nih.gov/pubmed/34788230 http://dx.doi.org/10.18632/aging.203576 |
work_keys_str_mv | AT gewen circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis AT chihao circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis AT tanghua circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis AT xujianjun circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis AT wangjing circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis AT caiwan circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis AT mahaitao circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis |